Key Takeaway: The article primarily serves as a disclaimer regarding the use of third-party websites linked from Cognition Therapeutics. It emphasizes that Cognition Therapeutics does not control or endorse the content of these external sites and encourages users to review their policies. There are no specific news updates or developments mentioned.
Price reaction · baseline $0.5686 (2024-08-12 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close · peak
+3.8%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Frequently Asked Questions
What does Cognition Therapeutics state about third-party websites?
Cognition Therapeutics disclaims responsibility for the content of third-party websites.
Should I review third-party site policies?
Yes, users are encouraged to read and evaluate the terms and policies of third-party sites.